Reported Earnings • Apr 07
Full year 2025 earnings released: NT$0.45 loss per share (vs NT$2.26 loss in FY 2024) Full year 2025 results: NT$0.45 loss per share (improved from NT$2.26 loss in FY 2024). Revenue: NT$1.94b (up 11% from FY 2024). Net loss: NT$16.6m (loss narrowed 80% from FY 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Announcement • Mar 12
Mytrex Health Technologies, Inc., Annual General Meeting, Jun 24, 2026 Mytrex Health Technologies, Inc., Annual General Meeting, Jun 24, 2026. New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 65% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$683.2m market cap, or US$21.8m). New Risk • Jan 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 65% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$781.9m market cap, or US$24.9m). Reported Earnings • Mar 26
Full year 2024 earnings released: NT$2.25 loss per share (vs NT$1.54 loss in FY 2023) Full year 2024 results: NT$2.25 loss per share (further deteriorated from NT$1.54 loss in FY 2023). Revenue: NT$1.76b (up 36% from FY 2023). Net loss: NT$82.4m (loss widened 47% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Mar 11
Mytrex Health Technologies, Inc., Annual General Meeting, Jun 12, 2025 Mytrex Health Technologies, Inc., Annual General Meeting, Jun 12, 2025. Location: 23 floor no,168, ching kuo rd., taoyuan district, taoyuan city Taiwan New Risk • Mar 03
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 47% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$904.3m market cap, or US$27.5m). Buy Or Sell Opportunity • Feb 27
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 19% to NT$25.00. The fair value is estimated to be NT$20.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Feb 05
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 20% to NT$25.80. The fair value is estimated to be NT$21.46, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Dec 27
Now 27% overvalued after recent price rise Over the last 90 days, the stock has risen 29% to NT$27.20. The fair value is estimated to be NT$21.34, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Meanwhile, the company became loss making. New Risk • Dec 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (NT$873.2m market cap, or US$26.7m). Reported Earnings • Mar 29
Full year 2023 earnings released: NT$1.54 loss per share (vs NT$2.52 loss in FY 2022) Full year 2023 results: NT$1.54 loss per share (improved from NT$2.52 loss in FY 2022). Revenue: NT$1.29b (up 455% from FY 2022). Net loss: NT$57.9m (loss narrowed 37% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance. Announcement • Mar 21
Mytrex Health Technologies, Inc., Annual General Meeting, Jun 25, 2024 Mytrex Health Technologies, Inc., Annual General Meeting, Jun 25, 2024. New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$58m revenue, or US$1.8m). Market cap is less than US$100m (NT$1.03b market cap, or US$32.6m). New Risk • Nov 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.7% average weekly change). Earnings have declined by 21% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$58m revenue, or US$1.9m). Market cap is less than US$100m (NT$1.25b market cap, or US$39.6m). New Risk • Aug 17
New major risk - Revenue and earnings growth Earnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$58m revenue, or US$1.8m). Market cap is less than US$100m (NT$1.17b market cap, or US$36.4m). Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 10 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Heng-Chiang Huang was the last independent director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Aug 15
First half 2022 earnings released: NT$0.38 loss per share (vs NT$0.74 profit in 1H 2021) First half 2022 results: NT$0.38 loss per share (down from NT$0.74 profit in 1H 2021). Revenue: NT$131.7m (down 24% from 1H 2021). Net loss: NT$13.8m (down 151% from profit in 1H 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 10 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Heng-Chiang Huang was the last independent director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 31
Full year 2021 earnings released: NT$0.38 loss per share (vs NT$10.97 profit in FY 2020) Full year 2021 results: NT$0.38 loss per share (down from NT$10.97 profit in FY 2020). Revenue: NT$291.6m (down 72% from FY 2020). Net loss: NT$14.0m (down 104% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improved over the past week After last week's 28% share price gain to NT$33.65, the stock trades at a trailing P/E ratio of 4.8x. Average trailing P/E is 18x in the Luxury industry in Taiwan. Total returns to shareholders of 198% over the past three years. Valuation Update With 7 Day Price Move • Oct 04
Investor sentiment deteriorated over the past week After last week's 16% share price decline to NT$25.90, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 16x in the Luxury industry in Taiwan. Total returns to shareholders of 100% over the past three years. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment deteriorated over the past week After last week's 29% share price decline to NT$36.60, the stock trades at a trailing P/E ratio of 3.3x. Average trailing P/E is 17x in the Luxury industry in Taiwan. Total returns to shareholders of 70% over the past three years. Valuation Update With 7 Day Price Move • May 13
Investor sentiment improved over the past week After last week's 45% share price gain to NT$74.20, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 20x in the Luxury industry in Taiwan. Total returns to shareholders of 239% over the past three years. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS NT$16.46 (vs NT$0.44 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$1.02b (up 157% from FY 2019). Net income: NT$352.3m (up NT$343.0m from FY 2019). Profit margin: 34% (up from 2.3% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improved over the past week After last week's 24% share price gain to NT$63.60, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 22x in the Luxury industry in Taiwan. Total returns to shareholders of 199% over the past three years. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment improved over the past week After last week's 18% share price gain to NT$45.30, the stock is trading at a trailing P/E ratio of 3.2x, up from the previous P/E ratio of 2.7x. This compares to an average P/E of 20x in the Luxury industry in Taiwan. Total returns to shareholders over the past three years are 101%. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorated over the past week After last week's 15% share price decline to NT$50.60, the stock is trading at a trailing P/E ratio of 3.6x, down from the previous P/E ratio of 4.2x. This compares to an average P/E of 19x in the Luxury industry in Taiwan. Total returns to shareholders over the past three years are 131%. Is New 90 Day High Low • Feb 02
New 90-day low: NT$50.60 The company is down 59% from its price of NT$125 on 05 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is down 1.0% over the same period. Valuation Update With 7 Day Price Move • Jan 15
Investor sentiment deteriorated over the past week After last week's 17% share price decline to NT$55.20, the stock is trading at a trailing P/E ratio of 3.9x, down from the previous P/E ratio of 4.8x. This compares to an average P/E of 20x in the Luxury industry in Taiwan. Total returns to shareholders over the past three years are 128%. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment deteriorated over the past week After last week's 17% share price decline to NT$58.70, the stock is trading at a trailing P/E ratio of 4.2x, down from the previous P/E ratio of 5.1x. This compares to an average P/E of 20x in the Luxury industry in Taiwan. Total returns to shareholders over the past three years are 148%. Is New 90 Day High Low • Jan 11
New 90-day low: NT$58.70 The company is down 54% from its price of NT$129 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 9.0% over the same period. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment deteriorated over the past week After last week's 21% share price decline to NT$71.90, the stock is trading at a trailing P/E ratio of 5.1x, down from the previous P/E ratio of 6.5x. This compares to an average P/E of 20x in the Luxury industry in Taiwan. Total returns to shareholders over the past three years are 205%. Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment deteriorated over the past week After last week's 15% share price decline to NT$70.40, the stock is trading at a trailing P/E ratio of 5x, down from the previous P/E ratio of 5.9x. This compares to an average P/E of 20x in the Luxury industry in Taiwan. Total returns to shareholders over the past three years are 189%. Is New 90 Day High Low • Dec 11
New 90-day low: NT$83.00 The company is down 35% from its price of NT$128 on 11 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 5.0% over the same period. Valuation Update With 7 Day Price Move • Nov 24
Market pulls back on stock over the past week After last week's 16% share price decline to NT$96.60, the stock is trading at a trailing P/E ratio of 6.9x, down from the previous P/E ratio of 8.2x. This compares to an average P/E of 21x in the Luxury industry in Taiwan. Total returns to shareholders over the past three years are 291%. Is New 90 Day High Low • Nov 21
New 90-day low: NT$108 The company is down 32% from its price of NT$158 on 21 August 2020. The Taiwanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 5.0% over the same period. Reported Earnings • Nov 14
Third quarter 2020 earnings released: EPS NT$8.28 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$364.1m (up 305% from 3Q 2019). Net income: NT$174.3m (up NT$173.1m from 3Q 2019). Profit margin: 48% (up from 1.3% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 65% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Sep 29
New 90-day low: NT$118 The company is down 43% from its price of NT$206 on 01 July 2020. The Taiwanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is flat over the same period.